Find the Perfect Plan for Your Investment Journey
V
Latest price
52 Week Range
€249.70 - €400.00
Next Earnings Date
Sep 11 2025 (Estimate)
Next Earnings Date
Sep 11 2025 (Est.)
Latest price
Market Cap | €2.56B |
EV | €2.72B |
Shares Outstanding | 8.37M |
Beta | 0.86 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | €386.83 |
P/E 2025E | 15.77x |
P/Revenue 2025E | 1.72x |
Revenue | 9.50% |
EPS | 10.50% |
Operating Cash Flow | 16.30% |
Free Cash Flow | 8.80% |
Revenue | 5.40% |
EPS | 7.20% |
Operating Cash Flow | 7.80% |
Free Cash Flow | 4.70% |
Gross Margin 2025E | 67.37% |
Net Profit Margin 2025E | 10.98% |
ROE 2025E | 13.67% |
ROCE 2024 | 14.95% |
DPS 2025E | €1.60 |
Payout Ratio 2025E | 8.32% |
Div. Yield 2025E | 0.53% |
DPS Last 3Y CAGR | 5.10% |
Price
%
1M
3M
6M
1Y
3Y
5Y
V
Virbac SA
VIRP
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Ramdani, Habib
Employees
5,620
Website
corporate.virbac.comIPO Date
1992-07-07
Headquarters
13e rue LID - BP 27, Carros, Provence-Alpes-Côte d'Azur, 06511, France
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved